Piramal Pharma Receives Official EIR with VAI Status for Lexington Facility
Piramal Pharma has officially received the Establishment Inspection Report (EIR) from US FDA with VAI status for its Lexington manufacturing facility, marking successful closure of the regulatory inspection. The company filed mandatory disclosure under SEBI Regulation 30, confirming the facility can continue operations while maintaining regulatory compliance standards.
*this image is generated using AI for illustrative purposes only.
Piramal Pharma has officially received the Establishment Inspection Report (EIR) from the US FDA for its Lexington manufacturing facility, confirming the Voluntary Action Indicated (VAI) status and marking the successful closure of the regulatory inspection.
Official Regulatory Disclosure
The company submitted a formal disclosure to BSE and NSE under Regulation 30 of SEBI regulations, confirming receipt of the EIR with VAI classification. The intimation was filed as the first working day communication following receipt of the official report from the US FDA.
| Parameter: | Details |
|---|---|
| Facility Location: | Lexington, Kentucky, USA |
| Inspection Status: | VAI (Voluntary Action Indicated) |
| Report Type: | Establishment Inspection Report (EIR) |
| Regulatory Framework: | SEBI Regulation 30 Compliance |
Inspection Timeline and Process
The US FDA inspection process began with the initial intimation dated December 11, 2025, when Piramal Pharma first disclosed the ongoing regulatory review at its Lexington facility. The completion of the inspection with EIR receipt represents the culmination of the regulatory assessment process.
VAI Status Implications
The Voluntary Action Indicated classification indicates that while the FDA may have identified certain areas for improvement during the inspection, the overall compliance framework at the Lexington facility meets acceptable regulatory standards. This status allows the facility to continue manufacturing operations while addressing any observations made during the inspection process.
Manufacturing Operations Continuity
With the official closure of the FDA inspection and receipt of the EIR, Piramal Pharma's Lexington facility maintains its operational capabilities. The regulatory clearance supports the company's ongoing pharmaceutical manufacturing activities and ensures continuity in market supply commitments for its product portfolio.
Historical Stock Returns for Piramal Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.92% | +4.13% | +7.30% | -23.34% | -32.90% | -19.78% |
What specific voluntary actions will Piramal Pharma need to implement at the Lexington facility to address FDA observations?
How might this VAI status impact Piramal Pharma's ability to secure new drug approvals or expand manufacturing capacity in the US market?
Will the company need to undergo additional FDA inspections within a specific timeframe to demonstrate compliance improvements?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
